Details
Stereochemistry | ABSOLUTE |
Molecular Formula | C18H21NO4.H3O4P |
Molecular Weight | 413.3588 |
Optical Activity | UNSPECIFIED |
Defined Stereocenters | 4 / 4 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
OP(O)(O)=O.[H][C@@]12OC3=C4C(C[C@@]5([H])N(C)CC[C@@]14[C@@]5(O)CCC2=O)=CC=C3OC
InChI
InChIKey=TZKVACZYAHJHRA-RKXJKUSZSA-N
InChI=1S/C18H21NO4.H3O4P/c1-19-8-7-17-14-10-3-4-12(22-2)15(14)23-16(17)11(20)5-6-18(17,21)13(19)9-10;1-5(2,3)4/h3-4,13,16,21H,5-9H2,1-2H3;(H3,1,2,3,4)/t13-,16+,17+,18-;/m1./s1
Molecular Formula | H3O4P |
Molecular Weight | 97.9952 |
Charge | 0 |
Count |
|
Stereochemistry | ACHIRAL |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Optical Activity | NONE |
Molecular Formula | C18H21NO4 |
Molecular Weight | 315.3636 |
Charge | 0 |
Count |
|
Stereochemistry | ABSOLUTE |
Additional Stereochemistry | No |
Defined Stereocenters | 4 / 4 |
E/Z Centers | 0 |
Optical Activity | UNSPECIFIED |
DescriptionCurator's Comment: description was created based on several sources, including
http://reference.medscape.com/drug/oxycontin-xtampza-er-oxycodone-343321 | https://www.ncbi.nlm.nih.gov/pubmed/23880538 | https://www.drugs.com/oxycodone.html
Curator's Comment: description was created based on several sources, including
http://reference.medscape.com/drug/oxycontin-xtampza-er-oxycodone-343321 | https://www.ncbi.nlm.nih.gov/pubmed/23880538 | https://www.drugs.com/oxycodone.html
Oxycodone is a semisynthetic opioid used for the management of acute and chronic pain severe enough to require an opioid analgesic and for which alternative treatments are inadequate. Oxycodone is a highly selective full agonist of the μ-opioid receptor (MOR), with low affinity for the δ-opioid receptor (DOR) and κ-opioid receptor (KOR). After oxycodone binds to the MOR, a G protein-complex is released, which inhibits the release of neurotransmitters by the cell by reducing the amount of cAMP produced, closing calcium channels, and opening potassium channels. After a dose of conventional (instant-release) oral oxycodone, the onset of action is 10–30 minutes, and peak plasma levels of the drug are attained within roughly 30–60 minutes in contrast, after a dose of OxyContin (an oral controlled-release formulation), peak plasma levels of oxycodone occur in about three hours. The duration of instant-release oxycodone is 3 to 6 hours, although this can be variable depending on the individual. Oxycodone in the blood is distributed to skeletal muscle, liver, intestinal tract, lungs, spleen, and brain. Serious side effects of oxycodone include reduced sensitivity to pain (beyond the pain the drug is taken to reduce), euphoria, anxiolysis, feelings of relaxation, and respiratory depression. Common side effects of oxycodone include constipation (23%), nausea (23%), vomiting (12%), somnolence (23%), dizziness (13%), itching (13%), dry mouth (6%), and sweating (5%).
CNS Activity
Originator
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL233 Sources: https://www.ncbi.nlm.nih.gov/pubmed/23880538 |
500.0 nM [EC50] | ||
Target ID: CHEMBL237 Sources: https://www.ncbi.nlm.nih.gov/pubmed/23880538 |
16000.0 nM [EC50] | ||
Target ID: CHEMBL236 Sources: https://www.ncbi.nlm.nih.gov/pubmed/23880538 |
4000.0 nM [EC50] |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Primary | PERCODAN-DEMI Approved UseOxyContin Tablets are a controlled-release oral formulation of oxycodone hydrochloride indicated for the management of moderate to severe pain when a continuous, around-the-clock analgesic is needed for an extended period of time. OxyContin is NOT intended for use as a prn analgesic. Physicians should individualize treatment in every case, initiating therapy at the appropriate point along a progression from non-opioid analgesics, such as non-steroidal anti-inflammatory drugs and acetaminophen to opioids in a plan of pain management such as outlined by the World Health Organization, the Agency for Healthcare Research and Quality (formerly known as the Agency for HealthCare Policy and Research), the Federation of State Medical Boards Model Guidelines, or the American Pain Society. OxyContin is not indicated for pain in the immediate postoperative period (the first 12-24 hours following surgery), or if the pain is mild, or not expected to persist for an extended period of time. OxyContin is only indicated for postoperative use if the patient is already receiving the drug prior to surgery or if the postoperative pain is expected to be moderate to severe and persist for an extended period of time. Physicians should individualize treatment, moving from parenteral to oral analgesics as appropriate. (See American Pain Society guidelines.) Launch Date-6.224256E11 |
|||
Primary | PERCODAN-DEMI Approved UseOxyContin Tablets are a controlled-release oral formulation of oxycodone hydrochloride indicated for the management of moderate to severe pain when a continuous, around-the-clock analgesic is needed for an extended period of time. OxyContin is NOT intended for use as a prn analgesic. Physicians should individualize treatment in every case, initiating therapy at the appropriate point along a progression from non-opioid analgesics, such as non-steroidal anti-inflammatory drugs and acetaminophen to opioids in a plan of pain management such as outlined by the World Health Organization, the Agency for Healthcare Research and Quality (formerly known as the Agency for HealthCare Policy and Research), the Federation of State Medical Boards Model Guidelines, or the American Pain Society. OxyContin is not indicated for pain in the immediate postoperative period (the first 12-24 hours following surgery), or if the pain is mild, or not expected to persist for an extended period of time. OxyContin is only indicated for postoperative use if the patient is already receiving the drug prior to surgery or if the postoperative pain is expected to be moderate to severe and persist for an extended period of time. Physicians should individualize treatment, moving from parenteral to oral analgesics as appropriate. (See American Pain Society guidelines.) Launch Date-6.224256E11 |
|||
Primary | PERCODAN-DEMI Approved UseOxyContin Tablets are a controlled-release oral formulation of oxycodone hydrochloride indicated for the management of moderate to severe pain when a continuous, around-the-clock analgesic is needed for an extended period of time. OxyContin is NOT intended for use as a prn analgesic. Physicians should individualize treatment in every case, initiating therapy at the appropriate point along a progression from non-opioid analgesics, such as non-steroidal anti-inflammatory drugs and acetaminophen to opioids in a plan of pain management such as outlined by the World Health Organization, the Agency for Healthcare Research and Quality (formerly known as the Agency for HealthCare Policy and Research), the Federation of State Medical Boards Model Guidelines, or the American Pain Society. OxyContin is not indicated for pain in the immediate postoperative period (the first 12-24 hours following surgery), or if the pain is mild, or not expected to persist for an extended period of time. OxyContin is only indicated for postoperative use if the patient is already receiving the drug prior to surgery or if the postoperative pain is expected to be moderate to severe and persist for an extended period of time. Physicians should individualize treatment, moving from parenteral to oral analgesics as appropriate. (See American Pain Society guidelines.) Launch Date-6.224256E11 |
Cmax
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
19 ng/mL |
10 mg single, oral dose: 10 mg route of administration: Oral experiment type: SINGLE co-administered: |
OXYCODONE unknown | Homo sapiens population: UNKNOWN age: ADULT sex: UNKNOWN food status: FASTED |
|
22.2 ng/mL |
15 mg single, oral dose: 15 mg route of administration: Oral experiment type: SINGLE co-administered: |
OXYCODONE unknown | Homo sapiens population: UNKNOWN age: ADULT sex: UNKNOWN food status: UNKNOWN |
|
17.7 ng/mL |
10 mg single, oral dose: 10 mg route of administration: Oral experiment type: SINGLE co-administered: |
OXYCODONE unknown | Homo sapiens population: UNKNOWN age: ADULT sex: UNKNOWN food status: FED |
|
39.3 ng/mL |
30 mg single, oral dose: 30 mg route of administration: Oral experiment type: SINGLE co-administered: |
OXYCODONE unknown | Homo sapiens population: UNKNOWN age: ADULT sex: UNKNOWN food status: UNKNOWN |
|
15.7 ng/mL |
5 mg 4 times / day steady-state, oral dose: 5 mg route of administration: Oral experiment type: STEADY-STATE co-administered: |
OXYCODONE unknown | Homo sapiens population: UNKNOWN age: ADULT sex: UNKNOWN food status: UNKNOWN |
|
12.9 ng/mL |
3.33 mg 6 times / day steady-state, oral dose: 3.33 mg route of administration: Oral experiment type: STEADY-STATE co-administered: |
OXYCODONE unknown | Homo sapiens population: UNKNOWN age: UNKNOWN sex: UNKNOWN food status: UNKNOWN |
AUC
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
105 ng × h/mL |
10 mg single, oral dose: 10 mg route of administration: Oral experiment type: SINGLE co-administered: |
OXYCODONE unknown | Homo sapiens population: UNKNOWN age: ADULT sex: UNKNOWN food status: FASTED |
|
128.2 ng × h/mL |
15 mg single, oral dose: 15 mg route of administration: Oral experiment type: SINGLE co-administered: |
OXYCODONE unknown | Homo sapiens population: UNKNOWN age: ADULT sex: UNKNOWN food status: UNKNOWN |
|
133 ng × h/mL |
10 mg single, oral dose: 10 mg route of administration: Oral experiment type: SINGLE co-administered: |
OXYCODONE unknown | Homo sapiens population: UNKNOWN age: ADULT sex: UNKNOWN food status: FED |
|
268.2 ng × h/mL |
30 mg single, oral dose: 30 mg route of administration: Oral experiment type: SINGLE co-administered: |
OXYCODONE unknown | Homo sapiens population: UNKNOWN age: ADULT sex: UNKNOWN food status: UNKNOWN |
|
113.3 ng × h/mL |
5 mg 4 times / day steady-state, oral dose: 5 mg route of administration: Oral experiment type: STEADY-STATE co-administered: |
OXYCODONE unknown | Homo sapiens population: UNKNOWN age: ADULT sex: UNKNOWN food status: UNKNOWN |
|
99 ng × h/mL |
3.33 mg 6 times / day steady-state, oral dose: 3.33 mg route of administration: Oral experiment type: STEADY-STATE co-administered: |
OXYCODONE unknown | Homo sapiens population: UNKNOWN age: UNKNOWN sex: UNKNOWN food status: UNKNOWN |
T1/2
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
2.9 h |
10 mg single, oral dose: 10 mg route of administration: Oral experiment type: SINGLE co-administered: |
OXYCODONE unknown | Homo sapiens population: UNKNOWN age: ADULT sex: UNKNOWN food status: FASTED |
|
3.55 h |
15 mg single, oral dose: 15 mg route of administration: Oral experiment type: SINGLE co-administered: |
OXYCODONE unknown | Homo sapiens population: UNKNOWN age: ADULT sex: UNKNOWN food status: UNKNOWN |
|
3.3 h |
10 mg single, oral dose: 10 mg route of administration: Oral experiment type: SINGLE co-administered: |
OXYCODONE unknown | Homo sapiens population: UNKNOWN age: ADULT sex: UNKNOWN food status: FED |
|
3.85 h |
30 mg single, oral dose: 30 mg route of administration: Oral experiment type: SINGLE co-administered: |
OXYCODONE unknown | Homo sapiens population: UNKNOWN age: ADULT sex: UNKNOWN food status: UNKNOWN |
Funbound
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
55% |
10 mg single, oral dose: 10 mg route of administration: Oral experiment type: SINGLE co-administered: |
OXYCODONE unknown | Homo sapiens population: UNKNOWN age: ADULT sex: UNKNOWN food status: FASTED |
|
55% |
15 mg single, oral dose: 15 mg route of administration: Oral experiment type: SINGLE co-administered: |
OXYCODONE unknown | Homo sapiens population: UNKNOWN age: ADULT sex: UNKNOWN food status: UNKNOWN |
|
55% |
10 mg single, oral dose: 10 mg route of administration: Oral experiment type: SINGLE co-administered: |
OXYCODONE unknown | Homo sapiens population: UNKNOWN age: ADULT sex: UNKNOWN food status: FED |
|
55% |
30 mg single, oral dose: 30 mg route of administration: Oral experiment type: SINGLE co-administered: |
OXYCODONE unknown | Homo sapiens population: UNKNOWN age: ADULT sex: UNKNOWN food status: UNKNOWN |
|
55% |
5 mg 4 times / day steady-state, oral dose: 5 mg route of administration: Oral experiment type: STEADY-STATE co-administered: |
OXYCODONE unknown | Homo sapiens population: UNKNOWN age: ADULT sex: UNKNOWN food status: UNKNOWN |
|
55% |
3.33 mg 6 times / day steady-state, oral dose: 3.33 mg route of administration: Oral experiment type: STEADY-STATE co-administered: |
OXYCODONE unknown | Homo sapiens population: UNKNOWN age: UNKNOWN sex: UNKNOWN food status: UNKNOWN |
Doses
Dose | Population | Adverse events |
---|---|---|
30 mg 1 times / day single, oral Studied dose Dose: 30 mg, 1 times / day Route: oral Route: single Dose: 30 mg, 1 times / day Co-administed with:: acetaminophen(1950 mg; single) Sources: cocaine(1/4 g; single) |
healthy, 30 years n = 1 Health Status: healthy Age Group: 30 years Sex: M Population Size: 1 Sources: |
Other AEs: Pulmonary edema... |
20 mg 2 times / day multiple, oral (mean) Recommended Dose: 20 mg, 2 times / day Route: oral Route: multiple Dose: 20 mg, 2 times / day Sources: Page: /nda/98/20932_medr_P2.pdf - p.21 |
unhealthy, adult n = 120 Health Status: unhealthy Condition: chronic pain Age Group: adult Sex: M+F Population Size: 120 Sources: Page: /nda/98/20932_medr_P2.pdf - p.21 |
Disc. AE: Nausea, Dizziness... AEs leading to discontinuation/dose reduction: Nausea (grade 1-2, 1.7%) Sources: Page: /nda/98/20932_medr_P2.pdf - p.21Dizziness (grade 1-2, 1.7%) Abdominal pain (grade 1-2, 0.8%) |
20 mg 2 times / day multiple, oral (mean) Recommended Dose: 20 mg, 2 times / day Route: oral Route: multiple Dose: 20 mg, 2 times / day Sources: Page: /nda/98/20932_medr_P2.pdf - p.21 |
unhealthy, adult n = 125 Health Status: unhealthy Condition: chronic pain Age Group: adult Sex: M+F Population Size: 125 Sources: Page: /nda/98/20932_medr_P2.pdf - p.21 |
Disc. AE: Headache, Vomiting... AEs leading to discontinuation/dose reduction: Headache (grade 1-2, 0.8%) Sources: Page: /nda/98/20932_medr_P2.pdf - p.21Vomiting (grade 1-2, 0.8%) Nausea (grade 1-2, 0.8%) Somnolence (grade 1-2, 0.8%) |
5 mg 4 times / day multiple, oral Recommended Dose: 5 mg, 4 times / day Route: oral Route: multiple Dose: 5 mg, 4 times / day Sources: Page: /nda/98/20932_medr_P2.pdf - p.21 |
unhealthy, adult n = 63 Health Status: unhealthy Condition: chronic pain Age Group: adult Sex: M+F Population Size: 63 Sources: Page: /nda/98/20932_medr_P2.pdf - p.21 |
Disc. AE: Nausea, Dizziness... AEs leading to discontinuation/dose reduction: Nausea (grade 1-2, 6.3%) Sources: Page: /nda/98/20932_medr_P2.pdf - p.21Dizziness (grade 1-2, 4.8%) Confusion (grade 1-2, 3.2%) |
5 mg 4 times / day multiple, oral Recommended Dose: 5 mg, 4 times / day Route: oral Route: multiple Dose: 5 mg, 4 times / day Sources: Page: /nda/98/20932_medr_P2.pdf - p.21 |
unhealthy, adult n = 126 Health Status: unhealthy Condition: chronic pain Age Group: adult Sex: M+F Population Size: 126 Sources: Page: /nda/98/20932_medr_P2.pdf - p.21 |
Disc. AE: Vomiting, Flu syndrome... AEs leading to discontinuation/dose reduction: Vomiting (grade 1-2, 0.8%) Sources: Page: /nda/98/20932_medr_P2.pdf - p.21Flu syndrome (grade 1-2, 0.8%) Confusion (grade 1-2, 0.8%) Fatigue (grade 1-2, 0.8%) |
6 mg 2 times / day single, oral (mean) Studied dose Dose: 6 mg, 2 times / day Route: oral Route: single Dose: 6 mg, 2 times / day Sources: |
healthy, mean age 33 years n = 35 Health Status: healthy Age Group: mean age 33 years Sex: M+F Population Size: 35 Sources: |
Disc. AE: Vomiting... AEs leading to discontinuation/dose reduction: Vomiting (11.4%) Sources: |
15 mg 1 times / day single, oral Studied dose Dose: 15 mg, 1 times / day Route: oral Route: single Dose: 15 mg, 1 times / day Sources: Page: nda/2011/202080Orig1s000MedR.pdf - p.22 |
healthy, mean age 36 years n = 40 Health Status: healthy Age Group: mean age 36 years Sex: M+F Population Size: 40 Sources: Page: nda/2011/202080Orig1s000MedR.pdf - p.22 |
Disc. AE: Vomiting... AEs leading to discontinuation/dose reduction: Vomiting (2.5%) Sources: Page: nda/2011/202080Orig1s000MedR.pdf - p.22 |
AEs
AE | Significance | Dose | Population |
---|---|---|---|
Pulmonary edema | 30 mg 1 times / day single, oral Studied dose Dose: 30 mg, 1 times / day Route: oral Route: single Dose: 30 mg, 1 times / day Co-administed with:: acetaminophen(1950 mg; single) Sources: cocaine(1/4 g; single) |
healthy, 30 years n = 1 Health Status: healthy Age Group: 30 years Sex: M Population Size: 1 Sources: |
|
Abdominal pain | grade 1-2, 0.8% Disc. AE |
20 mg 2 times / day multiple, oral (mean) Recommended Dose: 20 mg, 2 times / day Route: oral Route: multiple Dose: 20 mg, 2 times / day Sources: Page: /nda/98/20932_medr_P2.pdf - p.21 |
unhealthy, adult n = 120 Health Status: unhealthy Condition: chronic pain Age Group: adult Sex: M+F Population Size: 120 Sources: Page: /nda/98/20932_medr_P2.pdf - p.21 |
Dizziness | grade 1-2, 1.7% Disc. AE |
20 mg 2 times / day multiple, oral (mean) Recommended Dose: 20 mg, 2 times / day Route: oral Route: multiple Dose: 20 mg, 2 times / day Sources: Page: /nda/98/20932_medr_P2.pdf - p.21 |
unhealthy, adult n = 120 Health Status: unhealthy Condition: chronic pain Age Group: adult Sex: M+F Population Size: 120 Sources: Page: /nda/98/20932_medr_P2.pdf - p.21 |
Nausea | grade 1-2, 1.7% Disc. AE |
20 mg 2 times / day multiple, oral (mean) Recommended Dose: 20 mg, 2 times / day Route: oral Route: multiple Dose: 20 mg, 2 times / day Sources: Page: /nda/98/20932_medr_P2.pdf - p.21 |
unhealthy, adult n = 120 Health Status: unhealthy Condition: chronic pain Age Group: adult Sex: M+F Population Size: 120 Sources: Page: /nda/98/20932_medr_P2.pdf - p.21 |
Headache | grade 1-2, 0.8% Disc. AE |
20 mg 2 times / day multiple, oral (mean) Recommended Dose: 20 mg, 2 times / day Route: oral Route: multiple Dose: 20 mg, 2 times / day Sources: Page: /nda/98/20932_medr_P2.pdf - p.21 |
unhealthy, adult n = 125 Health Status: unhealthy Condition: chronic pain Age Group: adult Sex: M+F Population Size: 125 Sources: Page: /nda/98/20932_medr_P2.pdf - p.21 |
Nausea | grade 1-2, 0.8% Disc. AE |
20 mg 2 times / day multiple, oral (mean) Recommended Dose: 20 mg, 2 times / day Route: oral Route: multiple Dose: 20 mg, 2 times / day Sources: Page: /nda/98/20932_medr_P2.pdf - p.21 |
unhealthy, adult n = 125 Health Status: unhealthy Condition: chronic pain Age Group: adult Sex: M+F Population Size: 125 Sources: Page: /nda/98/20932_medr_P2.pdf - p.21 |
Somnolence | grade 1-2, 0.8% Disc. AE |
20 mg 2 times / day multiple, oral (mean) Recommended Dose: 20 mg, 2 times / day Route: oral Route: multiple Dose: 20 mg, 2 times / day Sources: Page: /nda/98/20932_medr_P2.pdf - p.21 |
unhealthy, adult n = 125 Health Status: unhealthy Condition: chronic pain Age Group: adult Sex: M+F Population Size: 125 Sources: Page: /nda/98/20932_medr_P2.pdf - p.21 |
Vomiting | grade 1-2, 0.8% Disc. AE |
20 mg 2 times / day multiple, oral (mean) Recommended Dose: 20 mg, 2 times / day Route: oral Route: multiple Dose: 20 mg, 2 times / day Sources: Page: /nda/98/20932_medr_P2.pdf - p.21 |
unhealthy, adult n = 125 Health Status: unhealthy Condition: chronic pain Age Group: adult Sex: M+F Population Size: 125 Sources: Page: /nda/98/20932_medr_P2.pdf - p.21 |
Confusion | grade 1-2, 3.2% Disc. AE |
5 mg 4 times / day multiple, oral Recommended Dose: 5 mg, 4 times / day Route: oral Route: multiple Dose: 5 mg, 4 times / day Sources: Page: /nda/98/20932_medr_P2.pdf - p.21 |
unhealthy, adult n = 63 Health Status: unhealthy Condition: chronic pain Age Group: adult Sex: M+F Population Size: 63 Sources: Page: /nda/98/20932_medr_P2.pdf - p.21 |
Dizziness | grade 1-2, 4.8% Disc. AE |
5 mg 4 times / day multiple, oral Recommended Dose: 5 mg, 4 times / day Route: oral Route: multiple Dose: 5 mg, 4 times / day Sources: Page: /nda/98/20932_medr_P2.pdf - p.21 |
unhealthy, adult n = 63 Health Status: unhealthy Condition: chronic pain Age Group: adult Sex: M+F Population Size: 63 Sources: Page: /nda/98/20932_medr_P2.pdf - p.21 |
Nausea | grade 1-2, 6.3% Disc. AE |
5 mg 4 times / day multiple, oral Recommended Dose: 5 mg, 4 times / day Route: oral Route: multiple Dose: 5 mg, 4 times / day Sources: Page: /nda/98/20932_medr_P2.pdf - p.21 |
unhealthy, adult n = 63 Health Status: unhealthy Condition: chronic pain Age Group: adult Sex: M+F Population Size: 63 Sources: Page: /nda/98/20932_medr_P2.pdf - p.21 |
Confusion | grade 1-2, 0.8% Disc. AE |
5 mg 4 times / day multiple, oral Recommended Dose: 5 mg, 4 times / day Route: oral Route: multiple Dose: 5 mg, 4 times / day Sources: Page: /nda/98/20932_medr_P2.pdf - p.21 |
unhealthy, adult n = 126 Health Status: unhealthy Condition: chronic pain Age Group: adult Sex: M+F Population Size: 126 Sources: Page: /nda/98/20932_medr_P2.pdf - p.21 |
Fatigue | grade 1-2, 0.8% Disc. AE |
5 mg 4 times / day multiple, oral Recommended Dose: 5 mg, 4 times / day Route: oral Route: multiple Dose: 5 mg, 4 times / day Sources: Page: /nda/98/20932_medr_P2.pdf - p.21 |
unhealthy, adult n = 126 Health Status: unhealthy Condition: chronic pain Age Group: adult Sex: M+F Population Size: 126 Sources: Page: /nda/98/20932_medr_P2.pdf - p.21 |
Flu syndrome | grade 1-2, 0.8% Disc. AE |
5 mg 4 times / day multiple, oral Recommended Dose: 5 mg, 4 times / day Route: oral Route: multiple Dose: 5 mg, 4 times / day Sources: Page: /nda/98/20932_medr_P2.pdf - p.21 |
unhealthy, adult n = 126 Health Status: unhealthy Condition: chronic pain Age Group: adult Sex: M+F Population Size: 126 Sources: Page: /nda/98/20932_medr_P2.pdf - p.21 |
Vomiting | grade 1-2, 0.8% Disc. AE |
5 mg 4 times / day multiple, oral Recommended Dose: 5 mg, 4 times / day Route: oral Route: multiple Dose: 5 mg, 4 times / day Sources: Page: /nda/98/20932_medr_P2.pdf - p.21 |
unhealthy, adult n = 126 Health Status: unhealthy Condition: chronic pain Age Group: adult Sex: M+F Population Size: 126 Sources: Page: /nda/98/20932_medr_P2.pdf - p.21 |
Vomiting | 11.4% Disc. AE |
6 mg 2 times / day single, oral (mean) Studied dose Dose: 6 mg, 2 times / day Route: oral Route: single Dose: 6 mg, 2 times / day Sources: |
healthy, mean age 33 years n = 35 Health Status: healthy Age Group: mean age 33 years Sex: M+F Population Size: 35 Sources: |
Vomiting | 2.5% Disc. AE |
15 mg 1 times / day single, oral Studied dose Dose: 15 mg, 1 times / day Route: oral Route: single Dose: 15 mg, 1 times / day Sources: Page: nda/2011/202080Orig1s000MedR.pdf - p.22 |
healthy, mean age 36 years n = 40 Health Status: healthy Age Group: mean age 36 years Sex: M+F Population Size: 40 Sources: Page: nda/2011/202080Orig1s000MedR.pdf - p.22 |
Overview
CYP3A4 | CYP2C9 | CYP2D6 | hERG |
---|---|---|---|
Drug as perpetrator
Target | Modality | Activity | Metabolite | Clinical evidence |
---|---|---|---|---|
yes | ||||
yes |
Drug as victim
Target | Modality | Activity | Metabolite | Clinical evidence |
---|---|---|---|---|
major | ||||
minor | ||||
yes | ||||
yes | ||||
yes | yes (co-administration study) Comment: When both oxidative pathways of the metabolism of oxycodone were inhibited with paroxetine and itraconazole (CYP3A4 AND CYP2D6 inhibitors), the mean AUC(0,∞) of oxycodone increased by 2.9-fold (P < 0.001), and its Cmax by 1.8-fold (P < 0.001). Page: 7.0 |
|||
yes | yes (co-administration study) Comment: When both oxidative pathways of the metabolism of oxycodone were inhibited with paroxetine and itraconazole (CYP3A4 AND CYP2D6 inhibitors), the mean AUC(0,∞) of oxycodone increased by 2.9-fold (P < 0.001), and its Cmax by 1.8-fold (P < 0.001). |
Tox targets
Target | Modality | Activity | Metabolite | Clinical evidence |
---|---|---|---|---|
PubMed
Title | Date | PubMed |
---|---|---|
Advancement of opioid analgesia with controlled-release oxycodone. | 2001 |
|
Strategies for the treatment of cancer pain in the new millennium. | 2001 |
|
The preemptive analgesic effect of intraarticular bupivacaine and morphine after ambulatory arthroscopic knee surgery. | 2001 Apr |
|
A curse and a cure. Is the crackdown on an abused drug causing needless suffering? | 2001 Aug 6 |
|
OxyContin abuse. | 2001 Feb |
|
Economic evaluation of the fentanyl transdermal system for the treatment of chronic moderate to severe pain. | 2001 Feb |
|
Lack of interaction between levofloxacin and oxycodone: pharmacokinetics and drug disposition. | 2001 Feb |
|
The potent perils of a miracle drug. | 2001 Jan 8 |
|
Federal reports say oxycodone abuse is on the rise. | 2001 Jul 1 |
|
Profits vs. pain relief. | 2001 Jul 2 |
|
Stability indicating HPLC method for the estimation of oxycodone and lidocaine in rectal gel. | 2001 Jul 31 |
|
Preoperative diclofenac is a useful adjunct to spinal anesthesia for day-case varicose vein repair. | 2001 Jul-Aug |
|
A retrospective study of the effect of postoperative indomethacin rectal suppositories on the need for narcotic analgesia in patients who had a cesarean delivery while they were under regional anesthesia. | 2001 Jun |
|
Prescription for addiction? | 2001 Mar |
|
Double-blind, randomized comparison of the analgesic and pharmacokinetic profiles of controlled- and immediate-release oral oxycodone in cancer pain patients. | 2001 May |
|
[Treatment of pain in cancer with systemically administered opioids]. | 2001 May 19 |
|
Conversion ratio and cost of oxycodone. | 2001 May-Jun |
|
OxyContin, the media, and law enforcement. | 2001 May-Jun |
|
Drug dependence studies and regulations: an overview of the past and present. | 2001 Nov |
|
Opioid therapy for chronic painful conditions. | 2001 Oct |
|
States respond to growing abuse of painkiller. | 2001 Oct-Nov |
|
Managing postoperative pain. | 2001 Sep |
|
Interscalene brachial plexus block with continuous intraarticular infusion of ropivacaine. | 2001 Sep |
|
The influence of anaesthesia and surgery on the circadian rhythm of melatonin. | 2002 Jan |
|
Combination hydrocodone and ibuprofen versus combination oxycodone and acetaminophen in the treatment of moderate or severe acute low back pain. | 2002 Jan |
|
OxyContin Use and Abuse. | 2002 Mar-Apr |
|
The analgesic efficacy of valdecoxib vs. oxycodone/acetaminophen after oral surgery. | 2002 May |
|
Sevoflurane versus halothane: effect of oxycodone premedication on emergence behaviour in children. | 2002 May |
|
Simultaneous quantitation of opioids in blood by GC-EI-MS analysis following deproteination, detautomerization of keto analytes, solid-phase extraction, and trimethylsilyl derivatization. | 2002 Oct |
|
Detection of cocaine analytes and opiates in nails from postmortem cases. | 2002 Oct |
|
Determination of 6-oxo-morphinans, as the oximes, by difference circular dichroism spectroscopy. | 2002 Oct |
|
[Pain therapy in rheumatic diseases. Oxycodon is not a weak opioid]. | 2002 Sep 12 |
Sample Use Guides
For opioid naïve patients, initiate treatment with 5 mg to 15 mg every 4 to 6 hours as needed for pain.
Route of Administration:
Oral
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/23880538
Human embryonic kidney (HEK)-293 were used for activity evaluation. Receptor G protein-mediated responses were determined by measuring changes in cAMP using the cAMP–homogenous timeresolved fluorescence kit (Cisbio, Codolet, France). MOR, KOR, DOR all couple to Gai so G protein coupling was measured as inhibition of forskolin-stimulated cAMP accumulation in the presence of 1.5 mkM NKH-477 (water-soluble forskolin, Tocris catalog #1603) and 500 mkM 3-isobutyl-1-methylxanthine (IBMX). cAMP accumulation assays were run in parallel with b-arrestin-2 recruitment, using the same cells, drug dilutions, and assay buffers [1% dimethylsulfoxide (DMSO), F12 Ham’s buffer] to ensure accurate assay-to-assay comparisons of data. Plates were read using a time-resolved fluorescence ratio (665 nm/620 nm) on a PheraStar plate reader
Substance Class |
Chemical
Created
by
admin
on
Edited
Sat Dec 16 18:21:16 UTC 2023
by
admin
on
Sat Dec 16 18:21:16 UTC 2023
|
Record UNII |
GRM3MU4DWP
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English |
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
1211844-14-2
Created by
admin on Sat Dec 16 18:21:16 UTC 2023 , Edited by admin on Sat Dec 16 18:21:16 UTC 2023
|
PRIMARY | |||
|
300000041678
Created by
admin on Sat Dec 16 18:21:16 UTC 2023 , Edited by admin on Sat Dec 16 18:21:16 UTC 2023
|
PRIMARY | |||
|
68824785
Created by
admin on Sat Dec 16 18:21:16 UTC 2023 , Edited by admin on Sat Dec 16 18:21:16 UTC 2023
|
PRIMARY | |||
|
GRM3MU4DWP
Created by
admin on Sat Dec 16 18:21:16 UTC 2023 , Edited by admin on Sat Dec 16 18:21:16 UTC 2023
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
PARENT -> SALT/SOLVATE |
APPROXIMATE PURE ANHYDROUS DRUG CONTENT (IN PERCENT)
|